Phathom Pharmaceuticals, Inc. (PHAT) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Phathom Pharmaceuticals, Inc.'s filing signal turned positive.

Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. Its primary product, VOQUEZNA (vonoprazan), is a potassium-competitive acid blocker (PCAB) approved in the U.S. for erosive gastroesophageal reflux disease (GERD) and Helicobacter pylori (H. pylori) infection. The company began U.S. commercialization in November 2023 and expanded its GERD indication to include non-erosive GERD in July 2024. Phathom is supported by a targeted sales force and has achieved broad commercial coverage for VOQUEZNA, with access for over 120 million U.S. commercial lives. The company is also exploring life-cycle management opportunities for vonoprazan, including potential new indications like eosinophilic esophagitis (EoE).

Revenue is primarily driven by sales of VOQUEZNA, VOQUEZNA DUAL PAK, and VOQUEZNA TRIPLE PAK in the United States. The company experienced increased revenues in 2025 compared to the prior year, reflecting growth in prescription volume and prescriber adoption, particularly for GERD indications.